Latest

Antibody-Drug Conjugates in China

In the face of the booming antibody market, China has jumped into the antibody-drug conjugate space. Jin Zhang reports.

Closing The Loop on Patient Engagement: Overcoming the PA Washout

Dan Rubin discusses how a full-service prior authorization (PA) support program facilitates higher PA submission rates and more prescriptions dispensed.

Next-Gen Patient Support Programs Gain Momentum in the Quest for Value

There’s a growing realization that advances in connected devices, sensors and predictive analytics represent a game-changer when it comes to patient support programs (PSPs), writes Jim O'Donaghue.

The Copay Showdown

With copay accumulators, payers have drawn a line in the sand. How should pharma respond?

Pharm Exec Video

Behind the Scenes with Kallyope’s Nancy Thornberry

A sneak peek at Pharm Exec's August cover shoot with the New York City-based biotech CEO.

Why One Korean Biotech Picked New Jersey for U.S. Headquarters

New Jersey is still a top pick for companies when it comes to pharma.

Pharm Exec Talks Partnerships with Sanofi

Hear what Sanofi looks for when they decide to form a partnership with another company.

New & Noteworthy

Why Your Advertising Agency Should Be Your Analytics Partner

Brands should look to their agencies to be a true data-driven business partner, not just a creative partner, writes Kevin Troyanos.

Specialty Pharma’s Move to Mainstream

While definitions for “specialty drug” vary, this once-niche treatment market may be poised to steer the future of prescription medicine and patient care.

Specialty Product Launch Insights

Executives highlight approaches around recent landmark approvals for digital medicine and gene therapy.

Specialty Focus: Tackling Rare Mutation in CF

How one nonprofit and its out-front leader are joining forces with industry to advance a new personalized medicine approach for cystic fibrosis patients with nonsense mutations.

Sales & Marketing

Why Your Advertising Agency Should Be Your Analytics Partner

Brands should look to their agencies to be a true data-driven business partner, not just a creative partner, writes Kevin Troyanos.

Learning, Retaining, Applying Information: Preparing Reps for Success in the Field

The most effective way to train sales reps and boost their success is to consider the learner/user experience in all facets, in every training encounter, and on each training platform, writes Shaun McMahon.

Beyond Big Data: Meeting the Specialty Marketing Challenge

With specialty companies getting smarter in applying their big data insights to product marketing, the true commercial potential of machine learning and predictive modeling may soon be within reach.

eBooks

Emerging BioPharma: Your Guide to Clinical and Commercial Considerations

This eBook will focus on the specific needs and concerns of the smaller to mid-size biopharmaceutical company. Articles cover considerations from Phase II to commercial pathways. 

View all eBooks

PEspeaks

How DSCSA Changes the Licensing Landscape

A look at the Drug Supply Chain Security Act and how it impacts serialization and third-party logistics licensing.

FDA Launches Major Push for New Antimicrobials

FDA is joining with other federal health agencies and the biomedical research community to advance the science, regulatory policies and reimbursement strategies to support innovative new medicines to combat infectious diseases.

Small Biotechs Gain As the Span of Clinical Trial Outsourcing Grows

Small biotech companies benefit more from partnering with CROs rather than hiring a chief medical officer.

Building Healthcare's "Ground Truth" with AI

For pharma leaders, AI can bring about a new reality of seeing a multitude of possible paths, forecasting the interplay of multi-dimensional trends, and charting patient journeys that are based on reality, writes Aswin Chandrakantan.

Interviews

Paul Perreault: The Global CEO

Pharm Exec talks with CSL's top executive about the realities of running the global, Australian-headquartered specialty biotech company and sustaining a strong focus in a fast-encroaching era of disruptive technologies and new priorities in innovation and R&D.

Close to the Action: Dr. José Luis Cabero, CEO, AELIX Therapeutics

Pharm Exec talks to AELIX Therapeutics' Dr. José Luis Cabero about how the career and country shift he made a decade ago have motivated and sustained a new direction in his career.

Navigating the Complex Reimbursement and Policy Landscape of Healthcare Access

Tommy Bramley and Kristine Flemister discuss how stakeholders can better help patients and providers navigate barriers around access and affordability in a complex healthcare environment.

Regulatory

Closing The Loop on Patient Engagement: Overcoming the PA Washout

Dan Rubin discusses how a full-service prior authorization (PA) support program facilitates higher PA submission rates and more prescriptions dispensed.

FDA Launches Major Push for New Antimicrobials

FDA is joining with other federal health agencies and the biomedical research community to advance the science, regulatory policies and reimbursement strategies to support innovative new medicines to combat infectious diseases.

Biosimilars Battles Heat Up

With the rise in industry programs for developing biosimilars, tensions are high as innovator firms back strategies that appear designed to delay competition. Jill Wechsler reports.

From the Editor

Specialty Supply Chain Decisions

In today’s drug development environment, there is no doubt that supply chain decisions are paramount in a product launch strategy, writes Lisa Henderson.

From Science to Success

A common thread in our exploration of "Emerging Biopharma" is that these companies need to be those that look beyond pure discovery—and put equal effort into the pivot to potential commercialization.

lorem ipsum